Your browser doesn't support javascript.
loading
Effect of Macrotroponin in a Cohort of Community Patients with Elevated Cardiac Troponin.
Lam, Leo; Tse, Rexson; Gladding, Patrick; Kyle, Campbell.
Afiliación
  • Lam L; Chemical Pathology, LabPlus, Auckland City Hospital, Auckland, New Zealand.
  • Tse R; Biochemistry, Middlemore Hospital Laboratories, Auckland, New Zealand.
  • Gladding P; Forensic Pathology, LabPlus, Auckland City Hospital, Auckland, New Zealand.
  • Kyle C; Cardiology, Northshore Hospital, Auckland, New Zealand.
Clin Chem ; 68(10): 1261-1271, 2022 10 06.
Article en En | MEDLINE | ID: mdl-35929566
BACKGROUND: Macrotroponin is an important cause of discrepancy between current high-sensitivity cardiac troponin (hs-cTn) assays, however, its clinical significance is unclear. This study examined the effects of macrotroponin and repeat testing by different hs-cTnI assays in a cohort of community patients with elevated hs-cTnI. METHODS: The first residual serum specimen from each patient in the community admitted to hospital with elevated hs-cTnI (Siemens hs-cTnI Centaur) was retested after immunoglobulin depletion and by 5 other hs-cTn assays. Low recovery of cTnI (<40%) following immunoglobulin depletion was considered as macrotroponin. A retrospective chart review was performed for these participants. Investigator-adjudicated diagnosis served as the reference standard. RESULTS: In our cohort of community patients with elevated troponin (n = 188), participants with macrotroponin (n = 99) often had a multifactorial or indeterminate myocardial injury (56% vs 25%) and were less likely to have acute coronary syndrome (9% vs 28%). On repeat testing of cTn on other platforms, better diagnostic performance (c-statistics) for ischemic and non-ischemic cardiac causes was observed on the Beckman Access hs-cTnI (0.74; 95% confidence interval [CI] 0.67-0.81) or the Abbott hs-cTnI Architect (0.75; CI 0.68-0.82) compared to the Siemens hs-cTnI Vista (0.62; CI 0.54-0.70; P < 0.05). This could be attributed to differences in assay reactivity for macrotroponin. Interestingly, better diagnostic performance was observed in patients without macrotroponin. Although a small number of deaths occurred (n = 16), participants with macrotroponin had better overall survival. CONCLUSIONS: In the low-risk setting, the presence of macrotroponin was clinically associated with multifactorial or indeterminate causes of troponin elevation.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Troponina I / Síndrome Coronario Agudo Tipo de estudio: Diagnostic_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Clin Chem Asunto de la revista: QUIMICA CLINICA Año: 2022 Tipo del documento: Article País de afiliación: Nueva Zelanda Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Troponina I / Síndrome Coronario Agudo Tipo de estudio: Diagnostic_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Clin Chem Asunto de la revista: QUIMICA CLINICA Año: 2022 Tipo del documento: Article País de afiliación: Nueva Zelanda Pais de publicación: Reino Unido